8-K: Zevra Therapeutics to Sell Rare Pediatric Disease Priority Review Voucher for $150 Million

Zevra Therapeutics has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million in cash.

Summary

• Zevra Therapeutics has agreed to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million.
• The PRV was awarded following the FDA approval of MIPLYFFA for Niemann-Pick disease type C.
• The transaction is expected to close within 30 to 45 days, subject to customary closing conditions, including Hart-Scott-Rodino Antitrust Improvements Act clearance.
• The $150 million in gross proceeds will strengthen Zevra's balance sheet and support strategic priorities.
• Cantor Fitzgerald acted as Zevra's exclusive financial advisor and Latham & Watkins LLP acted as Zevra's legal advisor for this transaction.

Sentiment

Score: 8

Explanation: The announcement is positive as it provides a significant cash infusion without diluting existing shareholders. The company is executing on its strategy and strengthening its financial position.

Positives

• The $150 million cash infusion will significantly strengthen Zevra's balance sheet.
• The funds will support the commercialization of MIPLYFFA and OLPRUVA.
• The sale allows Zevra to focus on its strategic priorities and pipeline development.
• The transaction is non-dilutive to existing shareholders.

Risks

• The transaction is subject to customary closing conditions, including regulatory approval under the Hart-Scott-Rodino Antitrust Improvements Act.
• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

The company expects the transaction to close within 30 to 45 days, subject to customary closing conditions. The proceeds will be used to support the commercial launches of MIPLYFFA and OLPRUVA, and to advance Zevra's pipeline.

Management Comments

• LaDuane Clifton, Zevra's Chief Financial Officer, stated that the non-dilutive capital strengthens the balance sheet and supports continued investment in strategic priorities.

Industry Context

Priority Review Vouchers are designed to incentivize the development of treatments for rare pediatric diseases. The sale of the voucher allows Zevra to monetize this asset and reinvest in its core business.

Comparison to Industry Standards

• The sale price of $150 million is within the typical range for PRV transactions, although prices can vary significantly based on market conditions and the perceived value of the voucher to potential buyers.
• Other companies, such as BioMarin Pharmaceutical and United Therapeutics, have previously sold PRVs for similar amounts.
• The value of a PRV is derived from its ability to expedite the FDA review process for a new drug application, potentially providing a significant competitive advantage.

Stakeholder Impact

• Shareholders will benefit from the strengthened balance sheet and the company's ability to invest in its strategic priorities.
• The proceeds will support the commercialization of therapies for rare diseases, benefiting patients with limited treatment options.

Next Steps

• The transaction is subject to customary closing conditions, including expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
• Zevra will use the proceeds to support the commercial launches of MIPLYFFA and OLPRUVA and advance its pipeline of product candidates.

Key Dates